August 8, 2024

A New Endpoint for Accelerated Approvals in Multiple Myeloma – On Cancer – Memorial Sloan Kettering

August 7, 2024

Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence | Blood Cancer Journal – Nature.com

August 6, 2024

Nammi Therapeutics, Inc. Completes Series B Round with Investment from MMRF’s Myeloma Investment Fund; Advances Clinical Development of Lead Program, QXL138AM

August 5, 2024

Deciphering the genetics and mechanisms of predisposition to multiple myeloma – Nature.com

July 26, 2024

Bringing Advanced Medicines for Multiple Myeloma into Reach for All